A blood based mitochondrial functional index biomarker for Alzheimer's disease
The MFI biomarker is reduced in cell and animal models of AD. The MFI biomarker is reduced in human AD subjects and APOE ε4 carriers. The MFI biomarker can discriminate between subjects with normal cognition and AD with better performance than other plasma biomarkers. The MFI biomarker correlates with cognitive scores.
Authors
- E.M Herrold
- Paul J. Kueck (ORCID: https://orcid.org/0000-0002-9102-2058)
- Jill K. Morris (ORCID: https://orcid.org/0000-0001-5911-4190)
- Rebecca Bothwell
- Leonidas E. Bantis (ORCID: https://orcid.org/0000-0002-2364-2562)
- Russell Howard Swerdlow (ORCID: https://orcid.org/0000-0003-2948-7230)
- Riley E. Kemna
- Keri Cox
- Brittany M Hauger
- Casey S. John
- Hana D. Mayfield
- Taylor A. Strope
- Heather M. Wilkins
- Keith P. Smith
Institutions
- University of Kansas (US)
- University of Kansas Medical Center (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz.71061
- Citations
- 1
- Primary Topic
- Mitochondrial Function and Pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Institutes of Health
- National Cancer Institute
- National Institute of General Medical Sciences
- National Center for Advancing Translational Sciences